Tremfya (guselkumab) Letter of Medical Necessity
Tremfya (guselkumab) is an IL-23 inhibitor with strong long-term efficacy data in psoriasis and psoriatic arthritis. PAs typically require step therapy through a TNF inhibitor and documentation of disease severity.
FDA-Approved Indications
- ● plaque psoriasis
- ● psoriatic arthritis
Why Tremfya Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy: TNF inhibitor or IL-17 not tried first
- 2. Severity scoring not documented (PASI, BSA, IGA)
- 3. Preferred IL-23 inhibitor (risankizumab) on formulary
- 4. Phototherapy or topical trial missing
What to Include in a Tremfya Letter of Medical Necessity
Document diagnosis with severity metrics (PASI, BSA, IGA for psoriasis; ACR criteria for PsA), prior biologic and conventional therapy trials with documented inadequate response or intolerance, and the clinical rationale for selective IL-23p19 blockade over preferred alternatives.
Key clinical evidence to cite:
- ✓ VOYAGE 1 and 2 (psoriasis)
- ✓ DISCOVER 1 and 2 (PsA)
- ✓ ECLIPSE head-to-head vs secukinumab
Relevant guidelines:
- 📖 AAD-NPF 2019 Psoriasis Guidelines
- 📖 GRAPPA 2021 PsA Recommendations
Payers Covering Tremfya
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Tremfya Prior Authorization FAQ
Why was my Tremfya prior authorization denied?
The most common denial reasons for Tremfya are: Step therapy: TNF inhibitor or IL-17 not tried first; Severity scoring not documented (PASI, BSA, IGA); Preferred IL-23 inhibitor (risankizumab) on formulary; Phototherapy or topical trial missing.
What should a Tremfya Letter of Medical Necessity include?
Document diagnosis with severity metrics (PASI, BSA, IGA for psoriasis; ACR criteria for PsA), prior biologic and conventional therapy trials with documented inadequate response or intolerance, and the clinical rationale for selective IL-23p19 blockade over preferred alternatives.
Which payers cover Tremfya?
Tremfya is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part D, though formulary tier and prior authorization criteria vary.